News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Taro Pharmaceutical Industries Ltd. (TARO) To Supply Generic Elocon-R-To Clay-Park Labs, Inc. (JNJ) In The U.S.


10/19/2005 5:09:37 PM

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Dec. 23, 2004--Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO) and its affiliates and subsidiaries ("Taro") announced today that it will supply Agis Industries (1983) Ltd. ("Agis") and its subsidiary, Clay Park Labs, Inc. ("Clay Park") with Mometasone Furoate Cream USP, 0.1% ("mometasone cream"), a generic version of Schering-Plough's Elocon(R) cream, pursuant to the terms of a supply agreement (the "Agreement"). Under the Agreement, the product will be manufactured by Taro and distributed by Clay Park in the United States.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES